Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Ewing's sarcoma and related subtypes of primitive neuroectodermal tumours share a recurrent and specific t(11;22) (q24;q12) chromosome translocation, the breakpoints of which have recently been cloned. Phylogenetically conserved restriction fragments in the vicinity of EWSR1 and EWSR2, the genomic regions where the breakpoints of chromosome 22 and chromosome 11 are, respectively, have allowed identification of transcribed sequences from these regions and has indicated that a hybrid transcript might be generated by the translocation. Here we use these fragments to screen human complementary DNA libraries to show that the translocation alters the open reading frame of an expressed gene on chromosome 22 gene by substituting a sequence encoding a putative RNA-binding domain for that of the DNA-binding domain of the human homologue of murine Fli-1.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ewing’s sarcoma, a common pediatric cancer, is invariably associated with ETS gene translocations (182) that result in a fusion oncogene consisting of the 5′ end of EWS and the 3′ end of FLI1, or less frequently ERG, ETV1, ETV4, or FEV (Figure 1a) (183, 184).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [183]
Citations
Cites
Kozak, M. (1986) · Cell · doi:10.1016/0092-8674(86)90762-2 · Cited by 4,741
Transcriptional Regulation in Mammalian Cells by Sequence-Specific DNA Binding Proteins
Mitchell, P. J., & Tjian, R. (1989) · Science · doi:10.1126/science.2667136 · Cited by 3,114
RNA recognition: towards identifying determinants of specificity
Kenan, D. J., Query, C. C., & Keene, J. D. (1991) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(91)90088-d · Cited by 730
RNA-binding proteins as developmental regulators.
Bandziulis, R. J., Swanson, M. S., & Dreyfuss, G. (1989) · Genes & Development · doi:10.1101/gad.3.4.431 · Cited by 644
Turc-Carel, C., Aurias, A., Mugneret, F., Lizard, S., Sidaner, I., Volk, C., Thiery, J. P., Olschwang, S., Philip, I., Berger, M. P., et al. (1988) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(88)90285-3 · Cited by 466
Self-citationBen-David, Y., Giddens, E. B., Letwin, K., & Bernstein, A. (1991) · Genes & Development · doi:10.1101/gad.5.6.908 · Cited by 403
Chromosome Translocation in Peripheral Neuroepithelioma
Whang-Peng, J., Triche, T. J., Knutsen, T., Miser, J., Douglass, E. C., & Israel, M. A. (1984) · New England Journal of Medicine · doi:10.1056/nejm198408303110907 · Cited by 399
Chromosomal Translocations in Ewing's Sarcoma
(1983) · New England Journal of Medicine · doi:10.1056/nejm198308253090817 · Cited by 330
Corden, J. L. (1990) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(90)90236-5 · Cited by 327
Turc-Carel, C., Philip, I., Berger, M.-P., Philip, T., & Lenoir, G. M. (1984) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(84)90002-5 · Cited by 291
Research works printed but not linked: 8
- Aurias, A., Rimbaut, C., Buffe, C., Dubousset, J. & Mazabraud, A. N. Engl. J. Med. 309, 496–497 (1983).
- Turc-Carel, C., Philip, I., Berge, R. M. P., Philip, T. & Lenoir, G. M. N. Engl. J. Med. 309, 497–498 (1983).
- De Chadarevian, J. P., Vekemans, M. & Seemayer, T. A. N. Engl. J. Med. 311, 1702–1703 (1984).
- Cavazzana, A. O. et al. Adv. Neuroblastoma Res. 2, 463–473 (1988).
- Zucman, J. et al. Genes Chrom. Cancer (in the press).
- Douglass, E. C., Valentine, M., Green, A. A., Hayes, F. A. & Thompson, E. I. J. natn. Cancer Inst. 77, 1211–1213 (1986).
- Watson, D. K., Ascione, R. & Papas, T. S. Crit. Rev. Oncogenesis 1, 409–436 (1990).
- Rouleau, G. A. et al. Am. J. hum. Genet. 46, 323–328 (1990).
Cited by
Items 401–500 of 1,002
Argatoff, L. H., OʼConnell, J. X., Mathers, J. A., Gilks, C. B., & Sorensen, P. H. B. (1996) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199604000-00002 · Cited by 78
EBNA‐1, the major nuclear antigen of Epstein‐Barr virus, resembles ‘RGG’ RNA binding proteins.
Snudden, D. K., Hearing, J. C., Smith, P. R., Grässer, F. A., & Griffin, B. E. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06810.x · Cited by 77
Beyond DNA: Zinc Finger Domains as RNA-Binding Modules
Font, J. S., & Mackay, J. P. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-753-2_29 · Cited by 86
“Morohoshi, F., Arai, K., Takahashi, E.I., Tanigami, A., and Ohki, M. (1996) Cloning and mapping of a human RBP56 gene encoding a putative RNA binding protein similar to FUS/TLS and EWS proteins.”
The molecular pathogenesis of Ewing sarcoma
Mackintosh, C., Madoz‐Gúrpide, J., Ordóñez, J. L., Osuna, D., & Herrero‐Martín, D. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.9.11511 · Cited by 86
Leacock, S. W., Basse, A. N., Chandler, G. L., Kirk, A., Rakheja, D., & Amatruda, J. F. (2011) · Disease Models & Mechanisms · doi:10.1242/dmm.007401 · Cited by 90
“In the majority of Ewing’s tumors, the N-terminal portion of EWS becomes fused to the C-terminal portion of FLI-1, which includes an ETS family DNA binding domain (Delattre et al., 1992).”
Deloulme, J., Prichard, L. B., Delattre, O., & Storm, D. R. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.43.27369 · Cited by 85
Self-citationRoberts, P., Burchill, S. A., Brownhill, S. C., Cullinane, C. J., Johnston, C., Griffiths, M., McMullan, D., Bown, N. P., Morris, S. P., & Lewis, I. J. (2007) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20523 · Cited by 76
“The gene rearrangement results in the generation of a EWSR1-FLI1 fusion transcript and expression of EWSR1-FLI1 protein (Delattre et al., 1992, 1994; Ida et al., 1995).”
BackgroundLiu, J., Nau, M. M., Yeh, J. C., Allegra, C. J., Chu, E., & Wright, J. R. (2000) · PubMed · Cited by 76
Machiela, M. J., Grünewald, T. G. P., Surdez, D., Reynaud, S., Mirabeau, O., Karlins, E., Rubío, R. A., Zaïdi, S., Grossetête, S., Ballet, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05537-2 · Cited by 76
Self-citationDiagnosis of Synovial Sarcoma with the Reverse Transcriptase-Polymerase Chain Reaction
Hiraga, H., Nojima, T., Abe, S., Sawa, H., Yamashiro, K., Yamawaki, S., Kaneda, K., & Nagashima, K. (1998) · Diagnostic Molecular Pathology · doi:10.1097/00019606-199804000-00007 · Cited by 76
EWS/FLI1 Target Genes and Therapeutic Opportunities in Ewing Sarcoma
Cidre‐Aranaz, F., & Alonso, J. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00162 · Cited by 78
“Ewing sarcomas are characterized by chromosomal translocations that fuse the EWSR1 gene to some members of the ETS family of transcription factors (3), being FLI1 the most frequently implicated [t(11;22)(q24;q12)] (4).”
BackgroundInfluentialHerpes simplex virus trans-regulatory protein ICP27 stabilizes and binds to 3' ends of labile mRNA
Brown, C. R., Nakamura, M., Mosca, J. D., Hayward, G. S., Straus, S. E., & Perera, L. P. (1995) · Journal of Virology · doi:10.1128/jvi.69.11.7187-7195.1995 · Cited by 75
“In creating p27GST(10-512), a segment of ICP27 lacking only the”
BackgroundResultBoulay, G., Volorio, A., Iyer, S., Broye, L. C., Stamenkovic, I., Riggi, N., & Rivera, M. N. (2018) · Genes & Development · doi:10.1101/gad.315192.118 · Cited by 79
“Ewing sarcoma, the second most common pediatric bone cancer, is characterized by specific chromosomal translocations that generate fusions between the EWSR1 gene and members of the ETS family of transcription factors, most commonly FLI1 (Delattre et al. 1992).”
BackgroundToretsky, J. A., Thakar, M., Eskenazi, A. E., & Frantz, C. N. (1999) · PubMed · Cited by 85
Multiple chromosomal mechanisms generate an EWS/FLI1 or an EWS/ERG fusion gene in Ewing tumors
Desmaze, C., Brizard, F., Turc‐Carel, C., Melot, T., Delattre, O., Thomas, G. D., & Aurias, A. (1997) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(96)00326-3 · Cited by 74
Self-citationTÖTSCH, M., BÖCKER, W., BRÖMMELKAMP, E., FILLE, M., KRECZY, A., ÖFNER, D., SCHMID, K. W., & DOCKHORN-DWORNICZAK, B. (1996) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199602)178:2<221::aid-path441>3.0.co;2-w · Cited by 45
Chaturvedi, A. P., Hoffman, L. M., Jensen, C. C., Lin, Y.-C., Grossmann, A. H., Randall, R. L., Lessnick, S. L., Welm, A. L., & Beckerle, M. C. (2014) · Molecular Biology of the Cell · doi:10.1091/mbc.e14-01-0007 · Cited by 78
“…caused by a reciprocal chromosomal translocation involving a portion of the EWSR1 gene on chromosome 22 and genes encoding members of the ETS family of transcription factors, most commonly FLI1, which maps to chromosome 11 (Turc-Carel et al., 1988; Delattre et al., 1992; Sankar and Lessnick, 2011).”
BackgroundInfluentialPassacantilli, I., Frisone, P., Paola, E. D., Fidaleo, M., & Paronetto, M. P. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx831 · Cited by 80
“In 85% of the cases, EWS is fused to the Friend leukemia virus integration site 1 (FLI-1), less commonly to the ETS-related gene ERG, the ETS-variant gene 1 (ETV-1), the ETS variant gene 4 (ETV-4), and the fifth Ewing sarcoma variant (FEV) (2).”
MethodMesenchymal Tumors with EWSR1 Gene Rearrangements
Thway, K., & Fisher, C. (2019) · Surgical pathology clinics · doi:10.1016/j.path.2018.10.007 · Cited by 73
Cooperation of cancer drivers with regulatory germline variants shapes clinical outcomes
Musa, J., Cidre-Aranaz, F., Aynaud, M.-M., Orth, M. F., Knott, M. M. L., Mirabeau, O., Mazor, G., Varon, M., Hölting, T. L. B., Grossetête, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12071-2 · Cited by 66
Self-citationKnott, M. M. L., Hölting, T. L. B., Ohmura, S., Kirchner, T., Cidre‐Aranaz, F., & Grünewald, T. G. P. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09839-9 · Cited by 72
“EwS, fusion genes are acquired early in tumorigenesis either through balanced chromosomal translocations [3] or through a”
BackgroundUnraveling Ewing Sarcoma Tumorigenesis Originating from Patient-Derived Mesenchymal Stem Cells
Solé, A. S., Grossetête, S., Heintzé, M., Babin, L., Zaïdi, S., Revy, P., Renouf, B., Cian, A. D., Giovannangeli, C., Pierre‐Eugène, C., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3837 · Cited by 77
Self-citationSavola, S. P., Arto Klami, A., Tripathi, A., Niini, T., Serra, M., Picci, P., Samuel Kaski, A., Zambelli, D., Scotlandi, K., & Knuutila, S. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-17 · Cited by 76
“Background The Ewing sarcoma family of tumors (ESFT) is a group of highly aggressive and often metastatic small round cell tumors characterized by specific t(11;22)(q24;q12) chromosomal rearrangements, which create the EWS/FLI1 gene fusion and thereby a chimeric, oncogenic transcription factor [1].”
BackgroundTargeting the EWSR1-FLI1 Oncogene-Induced Protein Kinase PKC-β Abolishes Ewing Sarcoma Growth
Surdez, D., Benetkiewicz, M., Perrin, V., Han, Z., Pierron, G., Ballet, S., Lamoureux, F., Rédiní, F., Decouvelaere, A., Daudigeos‐Dubus, E., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0371 · Cited by 80
Self-citationIdentification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor
Osgood, C. L., Maloney, N., Kidd, C. G., Kitchen-Goosen, S. M., Segars, L. E., Gebregiorgis, M., Woldemichael, G. M., He, M., Sankar, S., Lessnick, S. L., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2624 · Cited by 73
“Since the identification of EWS-FLI1 in the early 1990s, independent studies have established that the tumor absolutely depends on the activity of EWS-FLI1 for continued proliferation (6, 7), yet the clinical realization of an EWS-FLI1–directed therapy has not been achieved.”
BackgroundVentura, S., Aryee, D. N. T., Felicetti, F., Feo, A. D., Mancarella, C., Manara, M. C., Picci, P., Colombo, M. P., Kovar, H., Carè, A., et al. (2015) · Oncogene · doi:10.1038/onc.2015.463 · Cited by 74
Self-citationKoelsche, C., Kriegsmann, M., Kommoss, F. K. F., Stichel, D., Kriegsmann, K., Vokuhl, C., Grünewald, T. G. P., Romero‐Pérez, L., Kirchner, T., de Álava, E., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02895-2 · Cited by 72
Javelaud, D., Wietzerbin, J., Delattre, O., & Besançon, F. (2000) · Oncogene · doi:10.1038/sj.onc.1203246 · Cited by 84
“Over 90% of these tumors have recurrent reciprocal translocations which join the EWS gene on chromosome 22 to an ETS family gene, either FLI-1 on chromosome 11 or ERG on chromosome 21 (Delattre et al., 1992; Zucman et al., 1993; Sorensen et al., 1994).”
BackgroundSelf-citationSand, L. G. L., Szuhai, K., & Hogendoorn, P. C. W. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160716176 · Cited by 72
“The search for secondary mutations that provide a permissive genetic background, and might explain how the EWSR1-ETS chimera protein transforms cells, remained unsuccessful for over twenty years after the initial identification of the EWSR1-FLI1 fusion gene [43].”
BackgroundExtraskeletal Ewing's Sarcoma Family of Tumors in Adults: Prognostic Factors and Clinical Outcome
Tural, D. G., Mandel, N. M., Dervişoğlu, S., Dinçbaş, F. Ö., Koca, S. B., Öksüz, D. Ç., Kantarcı, F., Turna, H., Selçukbırıcık, F., & Hız, M. (2012) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hys027 · Cited by 71
EWS/ETS-Driven Ewing Sarcoma Requires BET Bromodomain Proteins
Gollavilli, P. N., Pawar, A., Wilder-Romans, K., Natesan, R., Engelke, C. G., Dommeti, V. L., Krishnamurthy, P. M., Nallasivam, A., Apel, I. J., Xu, T., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0484 · Cited by 80
“EWS is driven by characteristic chromosomal translocations that generate fusions between the EWS breakpoint region 1 (EWSR1) gene with members of the ETS family of transcription factors, most commonly to FLI1 (3) and with less frequency to ERG (4).”
BackgroundTsuda, Y., Zhang, L., Meyers, P. A., Tap, W. D., Healey, J. H., & Antonescu, C. R. (2020) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22857 · Cited by 75
“Tumor size (median, range) 8 (1–26) 8 (1-18) 7 (3-22) 8 (5-18) 3 (3-26) .”
Stolow, D. T., & Haynes, S. R. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.5.835 · Cited by 71
Studies on the innervation of human renal allografts
Shannon, J. L., Headland, R., MacIver, A. G., Ferryman, S. R., Barber, P. C., & Howie, A. J. (1998) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199809)186:1<8::aid-path156>3.0.co;2-h · Cited by 29
Cooperative DNA Binding with AP-1 Proteins Is Required for Transformation by EWS-Ets Fusion Proteins
Kim, S., Denny, C. T., & Wisdom, R. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.7.2467-2478.2006 · Cited by 68
“by on January 25, 2010 mcb.asm.org Downloaded from tion results in the expression of a novel EWS-Fli1 fusion protein in which the amino-terminal domain of EWS is fused to carboxyl-terminal sequences of Fli1, including the Fli1 Ets domain ( 6 ).”
BackgroundPietsch, T., Scharmann, T., Fonatsch, C., Schmidt, D., Ockler, R., Freihoff, D., Albrecht, S., Wiestler, O. D., Zeltzer, P. M., & Riehm, H. (1994) · PubMed · Cited by 71
Katz, R. L., Quezado, M., Senderowicz, A. M., Villalba, L., Laskin, W. B., & Tsokos, M. (1997) · Human Pathology · doi:10.1016/s0046-8177(97)90042-3 · Cited by 71
Fusion Genes and RNAs in Cancer Development
Taniue, K., & Akimitsu, N. (2021) · Non-Coding RNA · doi:10.3390/ncrna7010010 · Cited by 81
“fusion protein can gain the ability to bind to the genome and change the transcriptional mechanism [47,48].”
BackgroundIdentification of c-Src Tyrosine Kinase Substrates Using Mass Spectrometry and Peptide Microarrays
Amanchy, R., Zhong, J., Molina, H., Chaerkady, R., Iwahori, A., Kalume, D. E., Grønborg, M., Joore, J., Cope, L., & Pandey, A. (2008) · Journal of Proteome Research · doi:10.1021/pr800198w · Cited by 70
DuBois, S. G., Krailo, M., Lessnick, S. L., Smith, R. A., Chen, Z., Marina, N. M., Grier, H. E., & Stegmaier, K. (2008) · Pediatric Blood & Cancer · doi:10.1002/pbc.21822 · Cited by 70
“terminal domain of EWS and the carboxy-terminal domain of FLI1 [2,3].”
BackgroundDownstream EWS/FLI1 - upstream Ewing's sarcoma
Kovar, H. (2010) · Genome Medicine · doi:10.1186/gm129 · Cited by 73
“The unifying genetic trait of this family of tumors is a chromosomal translocation, t(11;22)(q24;q12), that was first described more than 20 years ago [4] and molecularly elucidated in 1992 [5].”
BackgroundSelf-citationTherapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting
Theisen, E. R., Pishas, K. I., Saund, R. S., & Lessnick, S. L. (2016) · Oncotarget · doi:10.18632/oncotarget.7124 · Cited by 70
“While the histogenesis of Ewing sarcoma remains enigmatic, 85% of cases are defined by the t(11;22)(q24;q12) chromosomal translocation, resulting in a pathognomonic chimeric fusion gene, EWSR1-FLI1, which encodes the EWS-FLI protein [3].”
BackgroundRussell-Goldman, E. E., Hornick, J. L., Qian, X., & Jo, V. Y. (2018) · Cancer Cytopathology · doi:10.1002/cncy.22056 · Cited by 70
Machen, Fisher, Gautam, Tubbs, & Goldblum (1998) · Histopathology · doi:10.1046/j.1365-2559.1998.00562.x · Cited by 70
“This group of tumours is characterized by the presence of a t(11;22)(q24;q12) and the formation of a novel fusion transcript resulting from the apposition of the Ewing’s sarcoma gene (EWS) on chromosome 22 with the FLI-1 gene on chromosome 11.(7) This fusion transcript, which can be detected using either fluorescence…”
BackgroundMethodPrescott, J. D., Koto, K., Singh, M., & Gutierrez‐Hartmann, A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.12.5548-5564.2004 · Cited by 70
“For example, chromosomal translocations in which the amino-terminal region of EWS is fused to the carboxy-terminal ETS domain of Fli-1 are found in 95% of human Ewing’s sarcomas (15).”
BackgroundModulations of the epithelial phenotype during embryogenesis and cancer progression
Savagner, P., Boyer, B., Vallés, A. M., Jouanneau, J., & Thiery, J. P. (1994) · Cancer treatment and research · doi:10.1007/978-1-4615-2592-9_12 · Cited by 70
Arora, R. S., Alston, R. D., Eden, T. O. B., Geraci, M., & Birch, J. M. (2012) · International Journal of Cancer · doi:10.1002/ijc.27402 · Cited by 76
Perani, M., Ingram, C. J. E., Cooper, C. S., Garrett, M. D., & Goodwin, G. H. (2003) · Oncogene · doi:10.1038/sj.onc.1207031 · Cited by 69
“Furthermore, the QPGY domain resembles the N-terminal activation region of the EWS/FUS/TLS family of proteins (Delattre et al., 1992; Ohno et al., 1993; Thaete et al., 1999) and is even more closely related to the N-terminal region of the BAF250 protein (also called p270/p250) and its two homologs…”
BackgroundBojović, B. B., & Hassell, J. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m005509200 · Cited by 68
Asano, Y., & Trojanowska, M. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01320-08 · Cited by 73
Tirado, Ò. M., Mateo‐Lozano, S., & Notario, V. (2005) · Oncogene · doi:10.1038/sj.onc.1208471 · Cited by 73
“The gene encoding EWS, a member of the TET family of RNA-binding proteins (Bertolotti et al., 1996), was cloned from the Ewing’s sarcoma chromosomal breakpoint, where translocations produce gene fusions between EWS and other transcription factorencoding genes (Delattre et al., 1992).”
BackgroundGenetic Predisposition to Solid Pediatric Cancers
Capasso, M., Montella, A., Tirelli, M., Maiorino, T., Cantalupo, S., & Iolascon, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.590033 · Cited by 74
Emergent Properties of EWS/FLI Regulation via GGAA Microsatellites in Ewing's Sarcoma
Gangwal, K., Close, D., Enriquez, C. A., Hill, C. P., & Lessnick, S. L. (2010) · Genes & Cancer · doi:10.1177/1947601910361495 · Cited by 67
“As a consequence of the (11;22) translocation, the amino terminal transcriptional activation domain of FLI is replaced by the amino terminus of EWS.(6) Because the EWS portion of the fusion functions as a strong transcriptional activation domain when fused to heterologous DNA-binding domains, one model for EWS/FLI fun…”
InfluentialEngert, F., Schneider, C., Weiβ, L. M., Probst, M., & Fulda, S. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0587 · Cited by 69
“This fusion protein encodes the chimeric transcription factor EWS-FLI1 that causes upregulation of a range of target genes including PARP1 (7, 8), which promotes transcriptional activation by EWS-FLI1 in a positive feedback loop (9).”
BackgroundInfluentialTargeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma
Hensel, T., Giorgi, C., Schmidt, O., Calzada‐Wack, J., Neff, F., Buch, T., Niggli, F. K., Schäfer, B. W., Burdach, S. E. G., & Richter, G. H. S. (2015) · Oncotarget · doi:10.18632/oncotarget.6385 · Cited by 72
“com/oncotarget translocation [13-15].”
Noujaim, J. C., Jones, R. L., Swansbury, J. G., de Castro, D. G., Benson, C., Judson, I. R., Fisher, C., & Thway, K. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.4 · Cited by 67
“The t(11;22)(q24;q12) rearrangement leading to EWSR1-FLI1 fusion is the commonest (in B85%; Delattre et al, 1992), with about 10% harbouring t(21;22)(q22;q12) leading to EWSR1-ERG fusion (Sorensen et al, 1994; Maire et al, 2008).”
BackgroundRelevance of Fusion Genes in Pediatric Cancers: Toward Precision Medicine
Dupain, C., Harttrampf, A. C., Urbinati, G., Geoerger, B., & Massaad-Massade, L. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.01.005 · Cited by 73
Selective Usage of D-Type Cyclins by Ewing’s Tumors and Rhabdomyosarcomas
Zhang, J., Hu, S., Schofield, D. E., Sorensen, P. H. B., & Triche, T. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2594 · Cited by 68
“Among the observed fusion genes, EWS-FLI1 is present in nearly 85% of ETs (4), whereas the EWS-ERG gene occurs in the majority of the remaining 15% of ETs (5).”
BackgroundRen, C., Ren, T., Yang, K., Wang, S., Bao, X., Zhang, F., & Guo, W. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0321-3 · Cited by 72
“The combination of EWS transactivation domain and the FLI1 DNA-binding domain give rise to heterogeneous breakpoints, the most common being type1 (Exon 7 of EWS/Exon 6 of FLI1) and type2 (Exon 7 of EWS/Exon 5 of FLI1) [4, 6, 32, 46, 47].”
BackgroundCharacterization of the human NIPSNAP1 gene from 22q12: a member of a novel gene family
Seroussi, E., Pan, H. H., Kedra, D., Roe, B. A., & Dumanski, J. P. (1998) · Gene · doi:10.1016/s0378-1119(98)00098-5 · Cited by 66
Diagnostic value of the molecular genetic detection of the t(11;22) translocation in Ewing's tumours
Dockhorn‐Dworniczak, B., Schäfer, K.-L., Dantcheva, R., Blasius, S., Böcker, W., Burdach, S. E. G., Strehl, S., Winkelmann, W., van Valen, F., & Jürgens, H. (1994) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/bf00230345 · Cited by 71
Desmaze, C., Zucman‐Rossi, J., Delattre, O., Melot, T., Thomas, G. D., & Aurias, A. (1994) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(94)90022-1 · Cited by 66
Self-citationRound cell sarcomas – Biologically important refinements in subclassification
Mariño‐Enríquez, A., & Fletcher, C. D. �. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.04.022 · Cited by 67
Targeting the CALCB/RAMP1 axis inhibits growth of Ewing sarcoma
Dallmayer, M., Li, J., Ohmura, S., Rubío, R. A., Baldauf, M. C., Hölting, T. L. B., Musa, J., Knott, M. M. L., Stein, S., Cidre‐Aranaz, F., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1372-0 · Cited by 73
Embree, L. J., Azuma, M., & Hickstein, D. D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3229 · Cited by 66
“Ewing sarcoma, a malignant bone and soft tissue tumor arising in children and young adults, is characterized by a chromosomal translocation fusing the EWSR1 (Ewing sarcoma breakpoint region 1) gene (also known as EWS) to the DNA-binding domain of an ETS transcription factor gene (1).”
Age-Period-Cohort Analysis of Primary Bone Cancer Incidence Rates in the United States (1976–2005)
Anfinsen, K. P., Devesa, S. S., Bray, F., Troisi, R. J., Jónasdóttir, T. J., Bruland, Ø. S., & Grotmol, T. (2011) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-11-0136 · Cited by 65
“A translocation between chromosomes 11 and 22 is found in almost all cases (16).”
BackgroundChemotherapy for Bone Sarcoma in Adults
Wagner, M. J., Livingston, J. A., PATEL, S. R., & Benjamin, R. S. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2015.009944 · Cited by 67
Chromosome translocations in sarcomas and the emergence of oncogenic transcription factors
Xia, S. J., & Barr, F. G. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.003 · Cited by 65
“Ewing s tumour family t(11;22)(q24;q12) EWS–FLI1 [123] t(21;22)(q22;q12) EWS–ERG [124] t(7;22)(p22;q12) EWS–ETV1 [125] t(2;22)(q33;q12) EWS–E1AF [126]”
The actin cytoskeleton-associated protein zyxin acts as a tumor suppressor in Ewing tumor cells
Amsellem, V., Kryszke, M.-H., Hervy, M., Subra, F., Athman, R., Leh, H., Brachet‐Ducos, C., & Auclair, C. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.10.035 · Cited by 72
Flucke, U. E., van Noesel, M. M., Siozopoulou, V., Creytens, D., Tops, B. B. J., van Gorp, J. M., & Hiemcke‐Jiwa, L. S. (2021) · Diagnostics · doi:10.3390/diagnostics11061093 · Cited by 70
“2 and the term for this gene was coined [1].”
BackgroundGenetics of chondrosarcoma and related tumors
Sandberg, A. A. (2004) · Current Opinion in Oncology · doi:10.1097/01.cco.0000129678.72521.e5 · Cited by 67
Oyoshi, T., & Kurokawa, R. (2012) · Cell & Bioscience · doi:10.1186/2045-3701-2-1 · Cited by 66
CD99 triggering induces methuosis of Ewing sarcoma cells through IGF-1R/RAS/Rac1 signaling
Manara, M. C., Terracciano, M., Mancarella, C., Sciandra, M., Guerzoni, C., Pasello, M., Grilli, A., Zini, N., Picci, P., Colombo, M. P., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13160 · Cited by 63
“EWS shows very low rate of somatic mutations [1, 2] confirming the dependence of this tumor on the oncogenic chimeric EWS–FLI1 protein [3].”
BackgroundMarchetto, A., Ohmura, S., Orth, M. F., Knott, M. M. L., Colombo, M. V., Arrigoni, C., Bardinet, V., Saucier, D., Wehweck, F. S., Li, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16244-2 · Cited by 73
Undifferentiated embryonal sarcoma of the liver: Results of clinical management in one center
Webber, E. M., Morrison, K. B., Pritchard, S., & Sorensen, P. H. B. (1999) · Journal of Pediatric Surgery · doi:10.1016/s0022-3468(99)90634-6 · Cited by 64
Reichert, T. E., Scheuer, C., Day, R., Wagner, W., & Whiteside, T. L. (2001) · Cancer · doi:10.1002/1097-0142(20010601)91:11<2136::aid-cncr1242>3.0.co;2-q · Cited by 162
Watanabe, H., Francis, J. M., Woo, M. S., Etemad, B., Lin, W., Fries, D. F., Peng, S., Snyder, E. L., Tata, P. R., Izzo, F., et al. (2013) · Genes & Development · doi:10.1101/gad.203208.112 · Cited by 69
Function of PEA3 Ets Transcription Factors in Mammary Gland Development and Oncogenesis
Kurpios, N. A., Sabolic, N. A., Shepherd, T. G., Fidalgo, G. M., & Hassell, J. A. (2003) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1025948823955 · Cited by 77
“Ewing’s sarcoma and the related primitive neuroectodermal tumors are commonly associated with P1: IZO Journal of Mammary Gland Biology and Neoplasia (JMGBN) pp944-jmgbn-470721 September 11, 2003 19:38 Style file version June 22, 2002 pea3 ets Genes in Mammary Gland Development and Oncogenesis 181 translocations that j…”
BackgroundStimulation of Oct‐4 Activity by Ewing's Sarcoma Protein
Lee, J., Rhee, B. K., Bae, G., Han, Y., & Kim, J. (2005) · Stem Cells · doi:10.1634/stemcells.2004-0375 · Cited by 67
Molecular genetics of chromosome translocations involvingEWSand related family members
Kim, J., & Pelletier, J. (1999) · Physiological Genomics · doi:10.1152/physiolgenomics.1999.1.3.127 · Cited by 70
“The emerging picture in many sarcomas is that the NTD of the fusion product is donated by the Ewing’s sarcoma gene (EWS) or a related member from the same gene family, whereas the CTD often consists of a DNAbinding domain derived from a transcription factor (10, 23, 94, 113, 114).”
BackgroundMacLennan, G. T., & Bostwick, D. G. (2005) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2005.01.005 · Cited by 62
Expression of EWS-ETS Fusions in NIH3T3 Cells Reveals Significant Differences to Ewing’s Sarcoma
Braunreiter, C. L., Hancock, J. D., Coffin, C. M., Boucher, K. M., & Lessnick, S. L. (2006) · Cell Cycle · doi:10.4161/cc.5.23.3505 · Cited by 71
Kuroda, M., Ishida, T., Horiuchi, H., Kida, N., Uozaki, H., Takeuchi, H., Tsuji, K., Imamura, T., Mori, S., & Machinami, R. (1995) · Europe PMC (PubMed Central) · Cited by 62
Transcriptional down-regulation through nuclear exclusion of EWS methylated by PRMT1
Araya, N., Hiraga, H., Kako, K., Arao, Y., Kato, S., & Fukamizu, A. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.02.018 · Cited by 61
Diagnostic gold standard for soft tissue tumours: morphology or molecular genetics?
Pfeifer, J. D., Hill, D. A., O’Sullivan, M. J., & Dehner, L. P. (2000) · Histopathology · doi:10.1046/j.1365-2559.2000.01107.x · Cited by 69
Bastian, L. S., Kwiatkowski, B. A., Breininger, J., Danner, S., & Roth, G. (1999) · Blood · doi:10.1182/blood.v93.8.2637 · Cited by 61
Strauss, S. J., Ng, T., Mendoza‐Naranjo, A., Whelan, J., & Sorensen, P. H. B. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0093 · Cited by 61
Nucleophosmin as a Candidate Prognostic Biomarker of Ewing's Sarcoma Revealed by Proteomics
Kikuta, K., Tochigi, N., Shimoda, T., Yabe, H., Morioka, H., Toyama, Y., Hosono, A., Beppu, Y., Kawai, A., Hirohashi, S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1913 · Cited by 60
Pishas, K. I., Drenberg, C. D., Taslim, C., Theisen, E. R., Johnson, K. M., Saund, R. S., Pop, I. L., Crompton, B. D., Lawlor, E. R., Tirode, F., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0373 · Cited by 60
“At the genome level, the sole distinguishing feature of ES is the presence of the reciprocal EWS/ETS translocation, with the resulting fusion protein, EWS/FLI in 85% of cases, acting as the molecular driver for tumor development (1,2).”
BackgroundSelf-citationVANG, R. S., Taubenberger, J. K., Mannion, C. M., Bijwaard, K. E., Malpica, A. L., Ordóǹez, N. G., Tavassoli, F. A., & Silver, S. A. (2000) · International Journal of Gynecological Pathology · doi:10.1097/00004347-200004000-00002 · Cited by 60
ERG gene is translocated in an Ewing's sarcoma cell line
Dunn, T., Praissman, L. A., Hagag, N. G., & Viola, M. V. (1994) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(94)90063-9 · Cited by 60
Primitive Neuroectodermal Tumor of the Kidney Confirmed by Fluorescence In Situ Hybridization
Sheaff, M. T., McManus, A. P., Scheimberg, I. B., PARIS, A. M. I., SHIPLEY, J. M., & Baithun, S. I. (1997) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199704000-00013 · Cited by 60
Showpnil, I. A., Selich‐Anderson, J., Taslim, C., Boone, M. A., Crow, J. C., Theisen, E. R., & Lessnick, S. L. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac747 · Cited by 60
“The FET family of RNA binding proteins, FUS, EWS, and TAF15 contain largely conserved low complexity domains (LCD) at the amino terminus, while the ETS (E26 transformation specific) family of transcription factors contain a highly conserved winged helix-loop-helix DNA-binding domain (DBD) (Schwartz et al., 2015; Seth…”
BackgroundInfluentialAneuploidy and complex genomic rearrangements in cancer evolution
Baker, T. M., Waise, S., Tarabichi, M., & Loo, P. V. (2024) · Nature Cancer · doi:10.1038/s43018-023-00711-y · Cited by 72
20 years of histone lysine demethylases: From discovery to the clinic and beyond
Gray, Z. H., Honer, M. A., Ghatalia, P., Shi, Y., & Whetstine, J. R. (2025) · Cell · doi:10.1016/j.cell.2025.02.023 · Cited by 74
Peripheral primitive neuroectodermal tumour of the lung: report of two cases
Tsuji, S., Hisaoka, M., Morimitsu, Y., Hashimoto, H., Jimi, A., Watanabe, J., Eguchi, H., & Kaneko, Y. (1998) · Histopathology · doi:10.1046/j.1365-2559.1998.00485.x · Cited by 59
“Subsequently, a 35 cycle polymerase chain reaction (PCR) was carried out to amplify the putative EWS/FLI-1 chimeric sequences.(14) The sequences of the primers were 11.”
MethodAtypical Antipsychotic Drug Use and Diabetes
Ananth, J., Venkatesh, R., Burgoyne, K. S., & Gunatilake, S. (2002) · Psychotherapy and Psychosomatics · doi:10.1159/000064807 · Cited by 59
EWS‐FLI‐1 and EWS‐ERG chimeric mRNAs in Ewing's sarcoma and primitive neuroectodermal tumor
Ida, K., Kobayashi, S., Taki, T., Hanada, R., Bessho, F., Yamamori, S., Sugimoto, T., Ohki, M., & Hayashi, Y. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910630407 · Cited by 64
Adams, V., Hany, M. A., Schmid, M., Hassam, S., Briner, J., & Niggli, F. K. (1996) · Diagnostic Molecular Pathology · doi:10.1097/00019606-199606000-00005 · Cited by 59
Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and Expectations
Olmos, D., Martins, A. S., Jones, R. L., Alam, S. M., Scurr, M. R., & Judson, I. R. (2011) · Sarcoma · doi:10.1155/2011/402508 · Cited by 67
“The translocation t(11;22) which results in the EWS-FLI1 fusion gene is the commonest [15].”
Background
Metadata
- Authors
- Delattre, O., Zucman, J., Plougastel, B., Desmaze, C., Melot, T., Peter, M., Kovar, H., Joubert, I., de Jong, P., Rouleau, G., Aurias, A., & Thomas, G.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Venue
- Nature
- Published
- 1992-09
- Volume
- 359
- Issue
- 6391
- Pages
- 162-165
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2069351898
- Cited by
- 1,907
- References
- 30
- Citations by year
- 2026: 57 · 2025: 72 · 2024: 69 · 2023: 64 · 2022: 78 · 2021: 83 · 2020: 80 · 2019: 69 · 2018: 54 · 2017: 57 · 2016: 71 · 2015: 62 · 2014: 61 · 2013: 63 · 2012: 45
- FWCI
- 60.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomic variations and chromosomal abnormalities
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- Ewing sarcoma, primitive neuroectodermal tumor, 22)(q24, EWSR1, gene fusion, chromosomal translocation, RNA-binding domain
- MeSH terms
- Amino Acid Sequence, Animals, Base Sequence, Chromosomes, Human, Pair 11, Chromosomes, Human, Pair 22, Cloning, Molecular, Gene Frequency, Humans, Molecular Sequence Data, Nucleic Acid Hybridization, Sarcoma, Ewing, Sequence Homology, Nucleic Acid, Transcription, Genetic, Translocation, Genetic, Restriction Mapping, DNA Probes, Polymerase Chain Reaction, Open Reading Frames, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.